vs
ALAMO GROUP INC（ALG）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
ALAMO GROUP INC的季度营收约是Orthofix Medical Inc.的1.7倍（$373.6M vs $219.9M），ALAMO GROUP INC净利率更高（4.2% vs -1.0%，领先5.2%），Orthofix Medical Inc.同比增速更快（2.0% vs -3.0%），ALAMO GROUP INC自由现金流更多（$69.9M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -6.3%）
Alamo Drafthouse Cinema是1997年在美国得克萨斯州奥斯汀成立的连锁影院品牌，主打观影期间提供餐食与饮品服务，同时严格要求观众遵守观影礼仪，2024年6月该连锁品牌被索尼影视体验部门收购。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
ALG vs OFIX — 直观对比
营收规模更大
ALG
是对方的1.7倍
$219.9M
营收增速更快
OFIX
高出5.0%
-3.0%
净利率更高
ALG
高出5.2%
-1.0%
自由现金流更多
ALG
多$53.1M
$16.8M
两年增速更快
OFIX
近两年复合增速
-6.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $373.6M | $219.9M |
| 净利润 | $15.5M | $-2.2M |
| 毛利率 | 22.7% | 71.1% |
| 营业利润率 | 6.0% | 0.2% |
| 净利率 | 4.2% | -1.0% |
| 营收同比 | -3.0% | 2.0% |
| 净利润同比 | -44.8% | 92.4% |
| 每股收益（稀释后） | $1.28 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALGOFIX
| Q4 25 | $373.6M | $219.9M | ||
| Q3 25 | $420.0M | $205.6M | ||
| Q2 25 | $419.1M | $203.1M | ||
| Q1 25 | $390.9M | $193.6M | ||
| Q4 24 | $385.3M | $215.7M | ||
| Q3 24 | $401.3M | $196.6M | ||
| Q2 24 | $416.3M | $198.6M | ||
| Q1 24 | $425.6M | $188.6M |
净利润ALGOFIX
| Q4 25 | $15.5M | $-2.2M | ||
| Q3 25 | $25.4M | $-22.8M | ||
| Q2 25 | $31.1M | $-14.1M | ||
| Q1 25 | $31.8M | $-53.1M | ||
| Q4 24 | $28.1M | $-29.1M | ||
| Q3 24 | $27.4M | $-27.4M | ||
| Q2 24 | $28.3M | $-33.4M | ||
| Q1 24 | $32.1M | $-36.0M |
毛利率ALGOFIX
| Q4 25 | 22.7% | 71.1% | ||
| Q3 25 | 24.2% | 72.2% | ||
| Q2 25 | 25.8% | 68.7% | ||
| Q1 25 | 26.3% | 62.8% | ||
| Q4 24 | 23.8% | 69.0% | ||
| Q3 24 | 25.1% | 68.7% | ||
| Q2 24 | 26.0% | 67.8% | ||
| Q1 24 | 26.2% | 67.5% |
营业利润率ALGOFIX
| Q4 25 | 6.0% | 0.2% | ||
| Q3 25 | 8.9% | -8.3% | ||
| Q2 25 | 11.2% | -7.9% | ||
| Q1 25 | 11.4% | -25.2% | ||
| Q4 24 | 8.9% | -5.3% | ||
| Q3 24 | 10.0% | -9.6% | ||
| Q2 24 | 10.4% | -12.5% | ||
| Q1 24 | 11.0% | -15.6% |
净利率ALGOFIX
| Q4 25 | 4.2% | -1.0% | ||
| Q3 25 | 6.0% | -11.1% | ||
| Q2 25 | 7.4% | -6.9% | ||
| Q1 25 | 8.1% | -27.4% | ||
| Q4 24 | 7.3% | -13.5% | ||
| Q3 24 | 6.8% | -13.9% | ||
| Q2 24 | 6.8% | -16.8% | ||
| Q1 24 | 7.5% | -19.1% |
每股收益（稀释后）ALGOFIX
| Q4 25 | $1.28 | $-0.05 | ||
| Q3 25 | $2.10 | $-0.57 | ||
| Q2 25 | $2.57 | $-0.36 | ||
| Q1 25 | $2.64 | $-1.35 | ||
| Q4 24 | $2.33 | $-0.76 | ||
| Q3 24 | $2.28 | $-0.71 | ||
| Q2 24 | $2.35 | $-0.88 | ||
| Q1 24 | $2.67 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $309.7M | $82.0M |
| 总债务越低越好 | $190.7M | — |
| 股东权益账面价值 | $1.1B | $450.0M |
| 总资产 | $1.6B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资ALGOFIX
| Q4 25 | $309.7M | $82.0M | ||
| Q3 25 | $244.8M | $62.9M | ||
| Q2 25 | $201.8M | $65.6M | ||
| Q1 25 | $200.3M | $58.0M | ||
| Q4 24 | $197.3M | $83.2M | ||
| Q3 24 | $140.0M | $30.1M | ||
| Q2 24 | $118.5M | $26.4M | ||
| Q1 24 | $121.8M | $27.0M |
总债务ALGOFIX
| Q4 25 | $190.7M | — | ||
| Q3 25 | $194.4M | $157.2M | ||
| Q2 25 | $198.1M | $157.0M | ||
| Q1 25 | $201.8M | $156.9M | ||
| Q4 24 | $205.5M | $157.0M | ||
| Q3 24 | $209.2M | $118.5M | ||
| Q2 24 | $278.6M | $118.0M | ||
| Q1 24 | $306.5M | $118.2M |
股东权益ALGOFIX
| Q4 25 | $1.1B | $450.0M | ||
| Q3 25 | $1.1B | $442.5M | ||
| Q2 25 | $1.1B | $458.3M | ||
| Q1 25 | $1.1B | $458.3M | ||
| Q4 24 | $1.0B | $503.1M | ||
| Q3 24 | $1.0B | $525.9M | ||
| Q2 24 | $979.7M | $546.0M | ||
| Q1 24 | $956.6M | $570.3M |
总资产ALGOFIX
| Q4 25 | $1.6B | $850.6M | ||
| Q3 25 | $1.6B | $832.6M | ||
| Q2 25 | $1.6B | $837.2M | ||
| Q1 25 | $1.5B | $823.1M | ||
| Q4 24 | $1.5B | $893.3M | ||
| Q3 24 | $1.5B | $867.9M | ||
| Q2 24 | $1.5B | $882.0M | ||
| Q1 24 | $1.5B | $906.0M |
负债/权益比ALGOFIX
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.17× | 0.36× | ||
| Q2 25 | 0.18× | 0.34× | ||
| Q1 25 | 0.19× | 0.34× | ||
| Q4 24 | 0.20× | 0.31× | ||
| Q3 24 | 0.21× | 0.23× | ||
| Q2 24 | 0.28× | 0.22× | ||
| Q1 24 | 0.32× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $75.1M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $69.9M | $16.8M |
| 自由现金流率自由现金流/营收 | 18.7% | 7.6% |
| 资本支出强度资本支出/营收 | 1.4% | 4.9% |
| 现金转化率经营现金流/净利润 | 4.84× | — |
| 过去12个月自由现金流最近4个季度 | $146.9M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ALGOFIX
| Q4 25 | $75.1M | $27.7M | ||
| Q3 25 | $65.5M | $12.4M | ||
| Q2 25 | $22.7M | $11.6M | ||
| Q1 25 | $14.2M | $-18.4M | ||
| Q4 24 | $79.1M | $23.7M | ||
| Q3 24 | $96.3M | $11.7M | ||
| Q2 24 | $33.2M | $9.0M | ||
| Q1 24 | $1.1M | $-18.6M |
自由现金流ALGOFIX
| Q4 25 | $69.9M | $16.8M | ||
| Q3 25 | $53.1M | $2.5M | ||
| Q2 25 | $15.7M | $4.5M | ||
| Q1 25 | $8.2M | $-25.1M | ||
| Q4 24 | $73.1M | $15.2M | ||
| Q3 24 | $88.4M | $6.3M | ||
| Q2 24 | $28.8M | $-360.0K | ||
| Q1 24 | $-5.5M | $-29.1M |
自由现金流率ALGOFIX
| Q4 25 | 18.7% | 7.6% | ||
| Q3 25 | 12.6% | 1.2% | ||
| Q2 25 | 3.8% | 2.2% | ||
| Q1 25 | 2.1% | -13.0% | ||
| Q4 24 | 19.0% | 7.0% | ||
| Q3 24 | 22.0% | 3.2% | ||
| Q2 24 | 6.9% | -0.2% | ||
| Q1 24 | -1.3% | -15.4% |
资本支出强度ALGOFIX
| Q4 25 | 1.4% | 4.9% | ||
| Q3 25 | 3.0% | 4.8% | ||
| Q2 25 | 1.7% | 3.5% | ||
| Q1 25 | 1.5% | 3.5% | ||
| Q4 24 | 1.6% | 4.0% | ||
| Q3 24 | 2.0% | 2.7% | ||
| Q2 24 | 1.1% | 4.7% | ||
| Q1 24 | 1.6% | 5.6% |
现金转化率ALGOFIX
| Q4 25 | 4.84× | — | ||
| Q3 25 | 2.58× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 2.82× | — | ||
| Q3 24 | 3.51× | — | ||
| Q2 24 | 1.17× | — | ||
| Q1 24 | 0.03× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALG
| Wholegood Units | $293.2M | 78% |
| Parts | $61.6M | 16% |
| Other Revenue | $18.9M | 5% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
